drugset / Trial / NCT02177305

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

NCT02177305

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety and tolerability after ocular administration

Timeline

Start
1998-10
Primary completion
1998-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 0.02 ug Other
Subject Tiotropium Other / unclassified 0.04 ug Other
Subject Tiotropium Other / unclassified 0.08 ug Other
Subject Tiotropium Other / unclassified 0.16 ug Other
Subject Tiotropium Other / unclassified 0.28 ug Other
Subject Tiotropium Other / unclassified 0.4 ug Other

Indications

No indication recorded.